2Pauwels RA, Buist AS, Calverley, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease, NHLBI/WHO Global Initiative for Chronic ohstructive lung disease (Gold) Wokshop summary. Am J Respir Grit Care Med, 2001, 163 (8): 1256～1276.
3Steiropoulos P, Papanas N, Nena E, et al. Indacaterol: a new long-acting flz-agonist in the management of chronic obstructive pulmonary disease[J]. Expert Opin Pharmacother, 2012, 13(7): 1015-1029.
7Gagnon YM, Levy AR, Spencer MD, et al Economic evaluation of treating chronic obstructive pulmonary disease with inhaled corticosteroids and long-acting beta2- agonists in a health maintenance organization[J]. Respir Med, 2005, 99(12) : 1534-1545.
8Adcock IM, Caramori G, Kirkham PA. Strategies for improving the efficacy and therapeutic ratio of glucocorticoids[J]. Curr Opin Pharmacol, 2012, 12(3): 246- 251.
10Cazzola M, Rogliani P, Segreti A, et aI. An update on bronchodilators in Phase Ⅰ and Ⅱ clinical trials[J]. Expert Opin Investig Drugs, 2012, 21(10): 1489-1501.
